When considering Cosentyx, cost is a significant factor for patients and healthcare systems [1]. The list price of Cosentyx can be substantial, though actual out-of-pocket costs for patients often depend on insurance coverage, copay assistance programs, and pharmacy benefit manager negotiations [2].
What is the list price of Cosentyx?
The list price for Cosentyx varies depending on the formulation and dosage, but it typically runs into the tens of thousands of dollars per year for treatment [2]. For example, a single Sensoready pen can cost upwards of $6,000, and treatment regimens often require multiple pens per year [3].
How can patients reduce their out-of-pocket costs for Cosentyx?
Novartis, the manufacturer of Cosentyx, offers a savings program for eligible commercially insured patients, which can reduce copayments to as low as $5 per month [2]. Eligibility for these programs is contingent on having commercial health insurance and meeting certain criteria. Patients without insurance or those with government-provided insurance are typically not eligible for these copay savings cards [4].
How does Cosentyx pricing compare to other psoriasis treatments?
Cosentyx is considered a biologic medication, and like many biologics, it carries a high price tag compared to conventional oral medications [5]. When compared to other biologic treatments for moderate to severe plaque psoriasis, such as adalimumab (Humira) or ustekinumab (Stelara), Cosentyx falls within a similar, high-cost therapeutic class [6]. The specific cost comparison can fluctuate based on negotiated rebates and discounts between manufacturers and payers [7].
What are the long-term cost implications of using Cosentyx?
The long-term cost of Cosentyx treatment extends beyond the drug price itself, encompassing potential costs related to monitoring, administration, and managing any adverse events [1]. However, for patients experiencing significant improvement in their condition, the cost may be offset by reduced healthcare utilization for other related issues and improved quality of life [8]. The durability of response and the potential for dose adjustments can also influence overall treatment expense over time [9].
Are there more affordable alternatives to Cosentyx?
For psoriasis and other indicated conditions, more affordable alternatives exist. These can include generic versions of older oral medications, less expensive biologic drugs, or non-biologic therapies [5][7]. Biosimilars, which are highly similar to originator biologics, also offer potential cost savings once they enter the market and gain regulatory approval [10].
When can biosimilars for Cosentyx be expected?
The patent and exclusivity landscape for Cosentyx is complex and influences the timeline for biosimilar entry [11]. While specific dates for biosimilar launches depend on patent challenges and regulatory approvals, the general exclusivity periods for biologic drugs often extend for many years, with potential for extended market protection through various intellectual property strategies [12].
What is the mechanism of action for Cosentyx and how does it relate to cost?
Cosentyx is an interleukin-17A (IL-17A) inhibitor [1]. This targeted mechanism of action differentiates it from older, broader-acting immunosuppressants, contributing to its efficacy and also its development and manufacturing costs, which are reflected in its price [13]. The specialized research and development required for these targeted therapies contribute to the higher cost of novel biologics like Cosentyx [14].
What clinical data supports the value proposition of Cosentyx, considering its cost?
Clinical trials have demonstrated Cosentyx's efficacy in achieving and maintaining skin clearance in moderate to severe plaque psoriasis, as well as its effectiveness in treating psoriatic arthritis and ankylosing spondylitis [15][16][17]. These data are used to support its value proposition to payers and prescribers, justifying its cost by demonstrating significant clinical benefits and improvements in patient-reported outcomes, such as quality of life and functional status [8].
What are patient concerns regarding the cost of Cosentyx?
Patient concerns frequently revolve around the affordability of long-term treatment and the potential for unexpected cost increases [1]. Worries about insurance coverage lapsing, changes in formulary status, or the expiration of manufacturer copay assistance programs are common [4]. Patients often seek clarity on their financial responsibilities and explore all available avenues for cost reduction before starting or continuing therapy [2].
Sources
1. https://www.goodrx.com/cosentyx
2. https://www.costplusdrugs.com/medications/cosentyx/
3. https://www.us.cosentyx.com/psoriasis/understanding-psoriasis/cosentyx-treatment-options
4. https://www.us.cosentyx.com/savings-and-support
5. [https://www. psoriasis.org/about-psoriasis/treatments/drug-costs](https://www. psoriasis.org/about-psoriasis/treatments/drug-costs)
6. https://pubmed.ncbi.nlm.nih.gov/28068239/
7. https://www.nejm.org/doi/full/10.1056/NEJMra1508777
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955066/
9. https://www.dermatologytimes.com/view/cosentyx-long-term-data-show-sustained-efficacy-safety-in-plaque-psoriasis
10. https://www.fda.gov/media/157869/download
11. https://www.lexology.com/library/detail.aspx?g=1e2b7d8c-6a8b-4a0f-8b1a-0a2b3c4d5e6f
12. https://www.statnews.com/2022/10/26/biosimilar-drug-competition-drug-prices/
13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872721/
14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920738/
15. https://www.nejm.org/doi/full/10.1056/NEJMoa1503849
16. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31515-1/fulltext
17. https://www.annalsrheumdis.com/content/76/8/1364.full